VolitionRx Limited
VNRX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | -0.35 | 0.17 | 7.42 |
| FCF Yield | -4.73% | -8.13% | -7.81% | -10.84% |
| EV / EBITDA | -19.99 | -15.63 | -11.79 | -10.06 |
| Quality | ||||
| ROIC | 229.59% | -660.40% | -399.17% | -211.19% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.65 | 0.99 | 0.78 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.25% | 36.51% | 56.40% | 59.08% |
| Free Cash Flow Growth | 45.23% | -47.44% | 23.62% | -1.91% |
| Safety | ||||
| Net Debt / EBITDA | -2.62 | -1.57 | -0.94 | -0.47 |
| Interest Coverage | -5.84 | -14.04 | -57.12 | -62.51 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 44.35 | 41.96 | 68.61 | 51.92 |